Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations

Vaccine

Volumn 26, Issue 47, 2008, Pages 5944-5951

  Adam, D ^a   Fehnle, K ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Algora Clinical Research   (Germany)

Author keywords

Pneumococcal conjugate vaccine; Pneumonia; Respiratory tract infection; Risk factors

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; BRONCHITIS; COMORBIDITY; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXCITABILITY; FEMALE; FEVER; GASTROENTERITIS; GERMANY; HIGH RISK PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PAIN; PETECHIA; PNEUMONIA; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEIZURE; SIDE EFFECT; SLEEP DISORDER; STREPTOCOCCUS PNEUMONIAE; SUDDEN INFANT DEATH SYNDROME; SWELLING; VOMITING;

BACTERIAL CAPSULES; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; GERMANY; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; INFANT; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; RESPIRATORY TRACT INFECTIONS; RISK FACTORS; TREATMENT OUTCOME; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 55049107226     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.08.058     Document Type: Article

References (37)

1. McCracken Jr. G.H. Etiology and treatment of pneumonia. Pediatr Infect Dis J 19 (2000) 373-377
2. Overturf G.D., and the Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 106 2 (2000) 367-376
3. Black S., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 19 (2000) 187-195
4. Robert Koch-Institut. Pneumokokken-Impfung mit 7-valentem Konjugatimpfstoff für Kinder unter 2 Jahren. Epidemiol Bull 2006;4(31):255-60.
5. Shoham Y., Dagan R., Givon-Lavi N., Liss Z., Shagan T., Zamir O., et al. Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life. Pediatrics 115 (2005) 1213-1219
6. Reinert R.R., Luetticken R., Bryskier A., and Al-Lahham A. Macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes in the pediatric population in Germany during 2000-2001. Antimicrob Agents Chemother 47 (2003) 489-493
7. Reinert R.R., van der Linden M., Seegmüller I., Al-Lahham A., Siedler A., Weißmann B., et al. Molecular epidemiology of penicillin-non-susceptible Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Germany. Clin Microbiol Infect 13 (2007) 363-368
8. O'Brien K.L., Steinhoff M.C., Edwards K., Keyserling H., Thomas M.L., and Madore D. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr Infect Dis J 15 (1996) 425-430
9. Shinefield H.R., Black S., Ray P., Chang I., Lewis N., Fireman B., et al. Safety and Immunogenicity of heptavalent pneumococal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 18 (1999) 757-763
10. Eskola J., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 344 (2001) 403-409
11. Oosterhuis-Kafeja F., Beutels P., and Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccines 25 12 (2007) 2194-2212
12. Poehling K.A., Lafleur B.J., Szilayi P.G., Edwards K.M., Mitchel E., Barth R., et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114 (2004) 755-761
13. Grijalva C.G., Poehling K.A., Nuorti J.P., Zhu Y., Martin S.W., Edwards K.M., et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118 3 (2006) 865-873
14. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennet N.M., Lynfield R., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysacharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
15. Black S., Shinefield H., Baxter R., Austrian R., Bracken L., Hansen J., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California kaiser permanente. Pediatr Infect Dis J 23 6 (2004) 485-489
16. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294 16 (2005) 2043-2051
17. Hausdorff W.P., Bryiant J., Paradiso P.R., and Siber G.R. Which pneumococcal serotypes cause the most invasive disease: implications for conjugate vaccine formulation and use. Part I. Clin Infect Dis 30 (2000) 100-121
18. Robert Koch-Institut. Empfehlungen der ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand Juli 2001. Epidemiol Bull 2001;(28):203-18.
19. Marcy S.M., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guideline of data collection, analysis and presentation. Vaccine 22 (2004) 551-556
20. Rosenbaum P.R., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 1 (1983) 41-55
21. D'Agostini Jr. R.B. Tutorials in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control-group. Stat Med 17 (1998) 2265-2281
22. Dagan R., Sikuler-Cohen M., Zamir O., Janco J., Givon-Lavi N., and Fraser D. Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees. Pediatr Infect Dis J 20 (2001) 951-958
23. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 21 (2002) 810-815
24. Esposito S., Lizioli A., Lastrico A., Begliatti E., Rognoni A., Tagliabue C., et al. Impact on respiratory tract infections of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months of age. Respir Res 8 (2007) 12-20
25. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., and Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369 (2007) 1179-1186
26. Lucero M.G., Dulalia V.E., Parreno R.N., Lim-Quianzon D.M., Nohynek H., Makela H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on X-ray in children under two years of age. Cochrane Database Syst Rev 4 (2004) CD004977
27. Cutts F.T., Zaman S.M., Enwere G., Jaffar S., Levine O.S., Okoko J.B., et al., Gambian Pneumococcal Vaccine Trial Group. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomized, double-blind, placebo-controlled trial. Lancet 365 (2005) 1139-1146
28. Klugman K.P., Madhi S.A., Huebner R.E., Kohberger R., Mbelle N., Pierce N., and for the Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 349 (2003) 1341-1348
29. Hansen J., Black S., Shinefield H., Cherian T., Benson J., Fireman B., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using WHO standard interpretation of chest radiographs. Pediatr Infect Dis J 25 9 (2006) 779-781
30. Levine O.S., Farley M., Harrison L.H., Lefkowitz L., McGeer A., and Schwartz B. Risk factors for invasive pneumococcal disease in children: a population-based case-control study in North America. Pediatrics 103 3 (1999) E38
31. Shinefield H., Black S., Ray P., Fireman B., Schwalbe J., and Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 21 (2002) 182-186
32. Ruggeberg J.U., Collins C., Clarke P., Johnson N., Sinha R., Everest N., et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine 25 (2007) 264-271
33. Esposito S., Pugni L., Bosis S., Proto A., Cesati L., Bianchi C., et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 23 (2005) 1703-1708
34. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368 (2006) 1495-1502
35. Jahn-Eimermacher A., du Prel J.B., and Schmitt H.J. Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical practice in randomized controlled clinical trials. Vaccine 25 (2007) 6237-6244
36. Centers for Disease Control, Prevention (CDC). Emergence of antimicrobialresistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep 56 41 (2007) 1077-1080
37. Knuf M., Habermehl P., Cimino C., Petersen G., and Schmitt H.J. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 24 (2006) 4727-4736